Deutsche Bank kept Hold on Siemens Healthineers stock

Published on 10/12/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Deutsche Bank sees 6.00 percent organic growth but weak profitability. Siemens Healthineers stock costs EUR 39.21 on October 12, 2026 versus EUR 39.14.

Key points in brief

Deutsche Bank Research kept a Hold rating and a EUR 39.00 target on October 5, 2026.
Siemens Healthineers reported Q3 revenue of EUR 5.764 billion and net profit of EUR 669.0 million for the quarter ended June 30, 2026.
The stock was trading at EUR 39.21 at Lang & Schwarz on October 12, 2026, 0.18 percent above the Xetra close of EUR 39.14 on October 9, 2026.
The next quarterly report and analyst call are scheduled for November 5, 2026.

Bauhaus-Poster mit geometrischen Formen und Text MEDTECH in Primärfarben — Siemens Healthineers DE000SHL1006 gestaltet Bauhaus-Poster mit geometrischen Formen und stilisiertem Scanner-Ring sowie MEDTECH-Schriftzug, Illustration mit AI erstellt.

Siemens Healthineers stock (ISIN DE000SHL1006) was trading at EUR 39.21 at Lang & Schwarz on October 12, 2026 at 10:21 a.m. CEST, up EUR 0.07 or 0.18 percent versus the Xetra close of EUR 39.14 on October 9, 2026. Deutsche Bank Research kept its Hold rating and EUR 39.00 target on October 5, 2026, while forecasting 6.00 percent organic revenue growth and weak profitability, according to FinanzNachrichten.

Results set the central test

For the quarter ended June 30, 2026, revenue reached EUR 5.764 billion, compared with EUR 5.662 billion in the same period a year earlier. Adjusted quarterly EBIT rose to EUR 1.101 billion from EUR 953.0 million, while net profit increased to EUR 676.0 million from EUR 556.0 million, according to VCBeat.

The revenue increase was 1.80 percent year over year, while adjusted EBIT grew 15.52 percent and net profit advanced 21.58 percent. The comparison points to stronger earnings conversion than sales growth, making profitability the key counterweight to Deutsche Bank's 6.00 percent organic growth expectation for the final quarter.

What does the next report test?

Siemens Healthineers' investor-relations calendar lists November 5, 2026 for fourth-quarter results and the analyst call, followed by a US roadshow on November 6, 2026, according to Siemens Healthineers. The company also identifies the latest published interim report as its third-quarter report for the 2025/2026 financial year.

Buyback reaches 3.424 million shares

The capital-return program had reached 3,374,359 repurchased shares by September 28, 2026, after 160,000 shares were bought during the preceding reporting period, according to EQS News. A later release dated October 5, 2026 recorded 49,987 additional shares bought between September 28 and October 4, taking the cumulative total to 3,424,346 shares, according to EQS News.

Jefferies maintained a Buy rating and a EUR 50.00 target in a September 30, 2026 note, citing stronger imaging momentum in the final quarter, according to Finanzen. That target stands EUR 10.00 above the current Lang & Schwarz price, but the comparison uses a different analyst reference and does not replace the Xetra-based daily calculation.

Stock remains close to the Xetra close

At Lang & Schwarz, Siemens Healthineers was trading at EUR 39.21 on October 12, 2026 at 10:21 a.m. CEST, EUR 0.07 or 0.18 percent above the Xetra close of EUR 39.14 on October 9, 2026. The finance calendar, recent earnings comparison and buyback figures give the November report three measurable tests: organic growth, profitability and capital returns. The further course of trading is shown by the continuously updated real-time quote of Siemens Healthineers stock.